GlassScriptPhysician profile
Anthony W Ho
NPI 1598226979
$863.81
in general payments reported to CMS, 2019-2025
15 companies · $28.58 in 2025
The $28.58 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $29.62 · 2023: $379 · 2024: $427 · 2025: $28.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $819 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $818.92 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $243.58 | 2023-2024 | Vtama |
| Leo Pharma INC. | $94.24 | 2023-2024 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $88.36 | 2023 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $71.09 | 2023-2024 | Zoryve |
| Sun Pharmaceutical Industries INC. | $66.13 | 2023-2024 | Ilumya |
| Incyte Corporation | $58.03 | 2024 | Opzelura |
| Abbvie INC. | $54.00 | 2023-2024 | |
| Verrica Pharmaceuticals INC. | $39.06 | 2024 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.62 | 2022 | |
| Ucb, INC. | $24.41 | 2023 | |
| Novartis Pharmaceuticals Corporation | $24.38 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $21.92 | 2024 | Dupixent |
| Biofrontera INC. | $20.41 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Pfizer INC. | $15.27 | 2025 | |
| Organon LLC | $13.31 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.